Product Categories
Country: | China |
---|---|
Tel: | 021-65675885 |
Mobile: | 18964387627 |
E-mail: | |
QQ: | |
Skype: | Chat Now! |
Product Name | MF | CAS | Details |
---|
Cudarolimab | 2244739-29-3 | Details |
bisSP1 | C12H23N9O2 | 2253947-15-6 | Details |
Bafrekalant | C29H31ClN6O2 | 2256770-44-0 | Details |
JNJ-65355394 | C19H26N4OS | 2230598-99-7 | Details |
DMA-135 hydrochloride | C16H18ClN7O | 2237925-62-9 | Details |
(Iso)-Atagabalin HCl | 223445-68-9 | Details |
CXCR7 modulator 2 | C29H42N6O3 | 2227426-37-9 | Details |
3-Methyl-2-quinoxalinecarboxylic Acid-d4 | C10H4D4N2O2 | 2244217-93-2 | Details |
BCL6-IN-3 | C24H31ClF2N6O2 | 2253878-44-1 | Details |
Favezelimab | 2231068-83-8 | Details |
Lorpucitinib | C22H28N6O2 | 2230282-02-5 | Details |
Itepekimab | 2226742-52-3 | Details |
Tesnatilimab | 2242758-08-1 | Details |
TH-Z145 | C16H28O7P2 | 2260887-57-6 | Details |
cpd.5 of 2234271-86-2 | C12H11NO3 | 2234284-82-1 | Details |
KDM4-IN-4 | C16H23NO | 2230475-63-3 | Details |
HPK1-IN-26 | C19H21N5OS | 2229042-24-2 | Details |
4-PQBH | C22H17N5O | 2243355-51-1 | Details |
PARP1/2/TNKS1/2-IN-1 | 2243453-32-7 | Details |
Adebrelimab | 2247114-85-6 | Details |
Upifitamab | 2254118-43-7 | Details |
Aβ/tau aggregation-IN-1 | C25H21IN2O | 2252162-81-3 | Details |
DNDI-6148 | C16H14BN5O3 | 2243909-59-1 | Details |
Revdofilimab | 2230138-89-1 | Details |
PDDC inhibitor | C27H29N5O4 | 2232878-43-0 | Details |
GSK-3 inhibitor 3 | C23H15FN6O | 2227279-84-5 | Details |
Pimicotinib | 2253123-16-7 | Details |
NLRP3-IN-17 | 2254432-75-0 | Details |
AW68 | 2247236-61-7 | Details |
HDAC6 degrader 9c | C37H45N9O10 | 2235382-05-3 | Details |
Ar-V7-IN-1 | C10H10Br2N4OS | 2230880-25-6 | Details |
BTK inhibitor 10 | C25H23N5O3 | 2241732-30-7 | Details |
OSMI-3 | C32H35N3O9S2 | 2260791-13-5 | Details |
Janelia Fluor 549 TFA | C29H23F3N2O7 | 2245946-45-4 | Details |
ARX-1796 | C14H23N3O8S | 2245880-46-8 | Details |
2-Quinoxalinecarboxylic acid-d4 | C9H6N2O2 | 2244217-89-6 | Details |
S2157 | C23H28ClF2N3O2 | 2262488-39-9 | Details |
Opevesostat | C21H26N2O5S | 2231294-96-3 | Details |
USP15-IN-1 | C22H23N3O3 | 2260826-16-0 | Details |
STAT3-IN-13 | C21H20N6O3S | 2248552-86-3 | Details |
IR820-PTX | 2250419-19-1 | Details |
EHMT2-IN-1 | C18H23N7O | 2230849-55-3 | Details |
SHR1653 | C21H21ClFN5O2 | 2231770-73-1 | Details |
Mirzotamab | 2229859-11-2 | Details |
Ziltivekimab | 2226654-05-1 | Details |
UNC5293 | C30H42N6O2 | 2226789-82-6 | Details |
AUTAC1 | 2241669-09-8 | Details |
RORγt inverse agonist 23 | C26H33NO5S | 2230779-18-5 | Details |
HPK1-IN-19 | C27H32N7O2P | 2227609-33-6 | Details |
SY-LB-57 | C16H13N3O | 2253719-35-4 | Details |
GSK-2807 free base | C19H32N8O5 | 2245255-65-4 | Details |
ZL0454 | C18H22N4O3S | 2229042-77-5 | Details |
Vibostolimab (anti-TIGIT) | 2231305-30-7 | Details |
Hu7691 free base | C22H21F3N4O | 2241232-43-7 | Details |
Pirepemat fumarate | C15H17F2NO5 | 2251806-70-7 | Details |
22393-62-0_peak 2 | C22H19Br | 22393-63-1 | Details |
CFTR corrector 6 | C22H13F4N9 | 2226970-01-8 | Details |
ALDH1A1-IN-2 | C25H23ClN4O3S | 2231081-18-6 | Details |
BY27 | C22H21ClN6 | 2247236-59-3 | Details |
Glofitamab | 2229047-91-8 | Details |
AMPC | C25H16FN3O3 | 2254434-33-6 | Details |
AZ2 | C20H23N3O2S | 2231760-33-9 | Details |
Atagabalin HCl | C10H20ClNO2 | 223445-67-8 | Details |
Amine-PEG3-Lys(PEG3-N3)-PEG3-N3 | C30H58N10O12 | 2244602-35-3 | Details |
TL12-186 | C44H51ClN10O9S | 2250025-88-6 | Details |
AHR antagonist 5 | C25H25ClFN7 | 2247953-39-3 | Details |
BI-1408 | C22H23FN6 | 2231075-94-6 | Details |
RAS GTPase inhibitor 1 | C27H28ClF4N5O2 | 2252242-32-1 | Details |
Mezagitamab | 2227490-52-8 | Details |
ITF3756 | C13H11N5O2S | 2247608-27-9 | Details |
(2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol | C26H34O14 | 2254096-97-2 | Details |
Nrf2 activator-1 | C30H34N4O6S | 2230697-41-1 | Details |
Feladilimab | 2252518-85-5 | Details |
Sabatolimab | 2252262-24-9 | Details |
Ragaglitazar | C25H25NO5 | 222834-30-2 | Details |
NCT-506 | C25H23FN4O3S | 2231098-99-8 | Details |
Pirmitegravir | C27H31ClN4O3 | 2245231-10-9 | Details |
Avizakimab | 2229685-51-0 | Details |
Bexmarilimab | 2259301-27-2 | Details |
Vixarelimab | 2243320-83-2 | Details |
Triflubazam | C17H13F3N2O2 | 22365-40-8 | Details |
AP-C5 | C16H13N5 | 2234272-10-5 | Details |
EMT inhibitor-2 | C24H26N2O8 | 2232228-60-1 | Details |
Tilvestamab | 2226775-26-2 | Details |
LY3372689 | C16H22FN5O3S | 2241514-56-5 | Details |
Isothiuronium | C12H25IN2S | 22584-04-9 | Details |
Rosopatamab | 2260767-49-3 | Details |
Idactamab | 2245205-37-0 | Details |
GSK-3 inhibitor 4 | C22H15F2N5O | 2227279-83-4 | Details |
Tubulin inhibitor 35 | 2247047-77-2 | Details |
Fenitrooxone | C9H12NO6P | 2255-17-6 | Details |
Serplulimab | 2231029-82-4 | Details |
MEISi-2 | C18H14N2O3 | 2250156-71-7 | Details |
ERα degrader-2 | C29H27F3N2O2 | 2235396-63-9 | Details |
BMT-090605 hydrochloride | C21H25ClN4O2 | 2231664-45-0 | Details |
MMP-9-IN-6 | 2241964-36-1 | Details |
Nampt activator-2 | C17H15ClN4O3S | 2237268-90-3 | Details |
Alogabat | C21H23N5O4 | 2230009-48-8 | Details |
Oditrasertib | C14H15F2N3O2 | 2252271-93-3 | Details |
Product Total: Product Page: | ||||
78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 |